Showing 5211-5220 of 5771 results for "".
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- Results of Lumega-Z Data to be Presented at ARVOhttps://modernod.com/news/results-of-lumega-z-data-to-be-presented-at-arvo/2476474/Guardion Health Sciences Scientific Advisory Board member William Sponsel, MD, will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The abstract is titled
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- Visioneering Technologies Creates Educational Series for Eye Care Practitionershttps://modernod.com/news/visioneering-technologies-creates-educational-series-for-eye-care-practitioners/2476471/Visioneering Technologies, maker of the NaturalVue Multifocal 1 Day contact lenses, announced the creation of a new educational series for eye care practitioners featuring some of the world’s leading researchers and clinicians, according to a company news release. The first installment of
- Proxy Advisory Firms Back Allergan in Battle with Dissident Shareholder Appaloosahttps://modernod.com/news/proxy-advisory-firms-back-allergan-in-battle-with-dissident-shareholder-appaloosa/2476472/Allergan said Monday that proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have recommended that shareholders vote for all of the board’s proposals at its annual meeting on May 1, and against hedge fund Appaloosa’s proposal calling for the immediate separa
- SilkTech Biopharmaceuticals’ IND Submission Cleared by FDA for Dry Eye Drophttps://modernod.com/news/silktech-biopharmaceuticals-ind-submission-cleared-by-fda-phase-2-clinical-trial-initiated-for-patients-with-dry-eye-disease/2476469/SilkTech Biopharmaceuticals announced the company has received clearance of its investigational new drug (IND) submission with the FDA for its SDP-4 eye drop product. In addition, the company has initiated a phase 2 clinical trial for its first-in-class drug to assess the safety and efficacy of t
- Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseaseshttps://modernod.com/news/ophthotech-obtains-exclusive-global-license-to-aav-gene-therapy-program-for-best1-related-retinal-diseases/2476467/Ophthotech announced that the company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania, including the Perelman School of Medicine at the University of Pennsylvania and the University of Pennsylvania School of Veterinary Medicine,
- Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents vs. Topical Prostaglandinhttps://modernod.com/news/trial-highlights-5-year-performance-of-2-standalone-glaukos-istents-vs-topical-prostaglandin/2476466/Glaukos announced that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean IOP to 16.5 mmHg
- Alimera Sciences Appoints Samer Kaba, MD, as Chief Medical Officerhttps://modernod.com/news/alimera-sciences-appoints-samer-kaba-md-as-chief-medical-officer/2476464/Alimera Sciences announced an expansion of its leadership team with the appointment of Samer Kaba, MD, as Chief Medical Officer, effective April 4, 2019. “I am very pleased that Samer will be joining us in this new position as he will bring both a physician’s perspect
- US Ophthalmologists Push to Remove Roadblocks to Patients’ Access to Medical and Surgical Eye Carehttps://modernod.com/news/us-ophthalmologists-push-to-remove-roadblocks-to-patients-access-to-medical-and-surgical-eye-care/2476461/More than 400 eye physicians and surgeons from across the United States are in Washington, DC, to urge Congress to end federal policies that delay patients’ access to quality medical and surgical eye care. As part of its annual visit to Capitol Hill, the American Academy of Ophthalmology (AAO) is